MIMS Summary: NICE approves adalimumab for psoriasis

NICE has published guidance on the use of adalimumab (Humira), an anti-TNF agent for the treatment of psoriasis.

It recommends adalimumab as a treatment option for adults with plaque psoriasis for whom anti-TNF treatment is being considered and when both of the following criteria are fulfilled:

  • The disease is severe (defined as a Psoriasis Area Sensitivity Index [PASI] and a Dermatology Life Quality Index [DLQI] of more than 10).
  • The disease has not responded to previous therapies including ciclosporin, methotrexate and PUVA, or the patient is intolerant or has a contraindication to these treatments.
  • Adalimumab should be discontinued in patients whose psoriasis has not responded adequately at 16 weeks.

Read the full NICE guidance

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus